-
1.发明公开ANTI-JAGGED 1/JAGGED 2 CROSS-REACTIVE ANTIBODIES, ACTIVATABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE THEREOF 审中-公开ANG-JAGGED-1 / JAGGED-2-KREUZREAKTIVEANTIKÖRPER，AKTIVIERBARE ANTI-JAGGED-ANTIKÖRPERUND ANWENDUNGSVERFAHRENDAFÜR
公开(公告)号：EP2863948A2
公开(公告)日：2015-04-29
申请号：EP13807400.0
申请日：2013-06-21
发明人： WEST, James, William , SAGERT, Jason, Gary , BESSETTE, Paul, H. , LOWMAN, Henry, Bernard , STAGLIANO, Nancy, E. , VASILJEVA, Olga , MENENDEZ, Elizabeth-Edna, Mary
IPC分类号： A61K39/395 , A61P35/00 , C07K16/18
CPC分类号： C07K16/18 , A61K39/39558 , A61K47/48384 , A61K47/48415 , A61K47/48569 , A61K47/6803 , A61K47/6811 , A61K47/6851 , A61K49/0058 , A61K2039/505 , C07K16/28 , C07K16/2887 , C07K16/2896 , C07K2317/21 , C07K2317/33 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/50 , A61K2300/00
摘要： This invention relates generally to the generation of antibodies,
e.g. , monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies,
e.g ., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies,
e.g. , nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti- Jagged antibodies and methods of using the anti- Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti- Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.摘要翻译： 本发明一般涉及将抗体（例如，将完整的人单克隆抗体（包括完整的人单克隆抗体）识别Jagged 1和/或Jagged 2）生成到抗体，例如包括识别Jagged 1和/或Jagged 2的完全人抗体的单克隆抗体 和编码抗体的核酸分子，例如编码单克隆抗体的核酸分子，包括识别Jagged 1和Jagged 2的完全人交叉反应性抗体，以及制备抗锯齿抗体的方法和使用抗锯齿抗体的方法 - 抗体作为治疗，预防和诊断。 本发明还通常涉及可激活的抗体，其包括特异性结合锯齿状1和锯齿状2的掩蔽部分（MM），可切割部分（CM）和抗体（AB），以及制备和使用这些可激活的抗体 - 各种治疗，诊断和预防指征中的锯齿状抗体。
-
公开(公告)号：EP2398494A2
公开(公告)日：2011-12-28
申请号：EP10744488.7
申请日：2010-02-23
IPC分类号： A61K38/21 , C07K14/00 , C07K14/555 , C07K16/00 , A61K38/16 , A61K39/395 , A61P35/04
CPC分类号： C07K14/56 , A61K38/00 , A61K47/64 , A61K47/65 , C07K14/00 , C07K14/555 , C07K14/565 , C07K14/57 , C07K14/705 , C07K16/00 , C07K19/00 , C07K2319/10 , C07K2319/31 , C07K2319/33 , C07K2319/50 , C07K2319/70 , C07K2319/90 , C12N15/1037 , G01N33/6866
摘要： The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins.
-
公开(公告)号：EP2385955B1
公开(公告)日：2020-08-12
申请号：EP10729683.2
申请日：2010-01-12
-
公开(公告)号：EP2863948B1
公开(公告)日：2018-10-24
申请号：EP13807400.0
申请日：2013-06-21
发明人： WEST, James, William , SAGERT, Jason, Gary , BESSETTE, Paul, H. , LOWMAN, Henry, Bernard , STAGLIANO, Nancy, E. , VASILJEVA, Olga , MENENDEZ, Elizabeth-Edna, Mary
CPC分类号： C07K16/18 , A61K39/39558 , A61K47/6803 , A61K47/6811 , A61K47/6851 , A61K49/0058 , A61K2039/505 , C07K16/28 , C07K16/2887 , C07K16/2896 , C07K2317/21 , C07K2317/33 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/50 , A61K2300/00
摘要： This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
-
-
-
搜索结果
4 条记录 (耗时 0.023 秒)
